Chanice Knight

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Scott M Elliott, J. Haughney, V. Libri, 2021, The Lancet.

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

J. Haughney, V. Libri, M. Kamal, 2022, The Lancet Infectious Diseases.

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

V. Libri, S. Royal, J. Nguyen-Van-Tam, 2021, The Lancet.

Absence of detectable monkeypox virus DNA in 11,000 English blood donations during the 2022 outbreak

P. Simmonds, T. Golubchik, H. Harvala, 2023, Transfusion.